ストックスクリーナーアプリを入手
5.76
4.00%
-0.24
アフターアワーズ：
5.76
前日終値:
$6.00
開ける：
$6.02
24時間の取引高:
742.24K
Relative Volume:
0.57
時価総額：
$560.14M
収益：
-
当期純損益:
$-168.09M
株価収益率:
-2.6544
EPS:
-2.17
ネットキャッシュフロー:
$-138.01M
1週間 パフォーマンス:
-10.97%
1か月 パフォーマンス:
-3.52%
6か月 パフォーマンス:
-67.42%
1年 パフォーマンス:
-72.27%
1日の値動き範囲:
$5.76
$6.12
1週間の範囲:
$5.48
$6.76
52週間の値動き範囲:
$5.41
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
名前
Kura Oncology Inc
セクター
電話
(858) 500-8800
住所
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
KURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
5.76 | 560.14M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-14 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-08-11 | 開始されました | BofA Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-05-17 | 開始されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2022-07-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 開始されました | Jefferies | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-11-05 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-11-09 | 開始されました | Piper Jaffray | Overweight |
| 2018-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-13 | 再開されました | Leerink Partners | Outperform |
| 2016-01-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-30 | 開始されました | Oppenheimer | Outperform |
| 2015-12-16 | 開始されました | Citigroup | Buy |
すべてを表示
Kura Oncology Inc (KURA) 最新ニュース
Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates - simplywall.st
Wells Fargo & Company MN Acquires 11,427 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Canada
MetLife Investment Management LLC Purchases 2,776 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com Australia
KURA Stock Set for Competitive Landscape in Menin Inhibitor Mark - GuruFocus
Kura Oncology to Participate in Bank of America Securities Healt - GuruFocus
Kura Oncology to Participate in Bank of America Securities Healthcare Conference - The Manila Times
Kura Oncology CEO Sets Stage for Major Updates at BofA Healthcare Conference Next Week - Stock Titan
Kura Oncology (NASDAQ:KURA) Cut to Hold at StockNews.com - Defense World
FY2026 EPS Estimates for Kura Oncology Increased by Analyst - Defense World
Barclays Cuts Kura Oncology (NASDAQ:KURA) Price Target to $11.00 - Defense World
Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Kura Oncology (NASDAQ:KURA) Shares Gap Down Following Weak Earnings - Defense World
Kura Oncology Inc (KURA)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2025 Earnings Call Transcript - Insider Monkey
Kura Oncology (KURA) Grants Inducement Stock Options to New Empl - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Barclays Adjusts Price Target for Kura Oncology (KURA) Following Q1 Update | KURA Stock News - GuruFocus
Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strat - GuruFocus
Kura Oncology Advances with Key NDA Submission - TipRanks
Kura Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kura Oncology: Q1 Earnings Snapshot - MySA
Kura Oncology Q1 2025 Earnings: Revenue Surges to $14.1M, EPS Ma - GuruFocus
Kura Oncology Inc earnings missed by $0.04, revenue topped estimates - Investing.com Canada
Kura Oncology Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Kura Oncology Q1 2025 reveals revenue boost By Investing.com - Investing.com South Africa
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Kura Oncology Reports First Quarter 2025 Financial Results - The Manila Times
Kura Oncology, Inc. SEC 10-Q Report - TradingView
Kura Oncology Achieves Major FDA Filing Milestone as Q1 Results Show $703M Cash Position - Stock Titan
Gastrointestinal Stromal Tumor Market Hits New High | Major Giants Novartis AG, Bayer AG, Kura Oncology - openPR.com
There is no doubt that Kura Oncology Inc (KURA) ticks all the boxes. - Sete News
JMP Securities Reaffirms “Market Outperform” Rating for Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology Inc [KURA] stock was sold by Hasnain Faheem at the price of US$0.18 million - knoxdaily.com
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Legal & General Group Plc - Defense World
Kura Oncology (KURA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Kura Oncology stock holds $28 target from JMP on trial data - Investing.com Canada
Kura Oncology (NASDAQ:KURA) Receives Buy Rating from HC Wainwright - Defense World
Kura doses first subjects in trial of ziftomenib for advanced GIST - Yahoo Finance
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST - marketscreener.com
Kura Reports Dosing in Phase 1 Ziftomenib Combination Trial - marketscreener.com
Kura Oncology Announces First Patients Dosed in Phase 1 Combinat - GuruFocus
Kura Oncology Announces First Patients Dosed In Phase 1 Combination Trial Of Ziftomenib For The Treatment Of Advanced Gist - marketscreener.com
Kura Oncology (KURA) Advances Ziftomenib in GIST Clinical Trial - GuruFocus
Kura Oncology (KURA) Advances Ziftomenib in GIST Clinical Trial | KURA Stock News - GuruFocus
Kura Oncology Initiates Phase 1 Study of Ziftomenib Combined with Imatinib for Advanced GIST Patients After Imatinib Failure - Nasdaq
Kura Oncology Inc (KURA) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):